26-LB: Exenatide and Renal Outcomes in Patients with Type 2 Diabetes and Diabetic Kidney Disease: A Multicenter, Randomized, Parallel Study
Aim: This trial aimed to assess the effects of exenatide, a GLP-1RA, on renal outcomes in patients with T2DM and DKD. Methods: We performed a randomized, parallel study conducted in 4 general hospitals. T2DM patients with an eGFR≥30mL/min/1.73m2 and macroalbuminuria, defined as 24h-urinary albumin-c...
Gespeichert in:
| Veröffentlicht in: | Diabetes (New York, N.Y.) N.Y.), 2020-06, Vol.69 (Supplement_1) |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | Supplement_1 |
| container_start_page | |
| container_title | Diabetes (New York, N.Y.) |
| container_volume | 69 |
| creator | WANG, XIANGYU ZHANG, QIAN GUAN, MEIPING SHENG, SHUYUE MO, WEI ZOU, MENGCHEN LI, JIMIN BI, JIANLU TANG, XIANYU HE, JIALI XU, GUGEN LI, PING ZHANG, HUIJIE XUE, YAOMING |
| description | Aim: This trial aimed to assess the effects of exenatide, a GLP-1RA, on renal outcomes in patients with T2DM and DKD.
Methods: We performed a randomized, parallel study conducted in 4 general hospitals. T2DM patients with an eGFR≥30mL/min/1.73m2 and macroalbuminuria, defined as 24h-urinary albumin-creatinine ratio (UAER) >0.3g/24h, were randomized 1:1 to receive exenatide twice daily plus glargine or lispro insulin plus glargine for 24 weeks. The primary outcome was percentage change in 24h-UAER after 24 weeks of intervention comparing to baseline measurement. The secondary outcomes included the percentage change in urinary ACR, change in 24h-UAER, ACR, HbA1c, FPG, body weight and blood pressure. The safety outcomes include rates of hypoglycemia, adverse events and change in eGFR during the follow up.
Results: Between March 2016 and April 2019, 92 patients were randomized and took at least one dose of study drug. The mean age of the participants was 56 years. At baseline, the median 24h-UAER was 1512.0 mg/24h (IQR 782.5-2818.0), and mean eGFR was 70.4 mL/min/1.73 m2 (SD 23.4). After 24 weeks, exenatide reduced the percentage change of the 24h-UAER (difference between groups was 29.7%, p=0.0255), the percentage change of ACR (difference between groups was 28.4%, p=0.0395) and the absolute change of ACR (difference between groups was 607.8 mg/g, p=0.0209) but had no significant difference on the absolute change of 24h-UAER than the control group. Meanwhile, the body weight declined by 1.3kg with exenatide (difference between groups was 2.7kg, p=0.0001). There was no difference between two groups on the change in HbA1c, FPG, blood pressure or eGFR. Comparing to the control group, lower frequency of hypoglycemia as well as more gastrointestinal adverse events were in intervention group.
Conclusions: Exenatide twice daily plus glargine for 24 weeks resulted in significant reduction of albuminuria in T2DM patients with DKD. |
| doi_str_mv | 10.2337/db20-26-LB |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2419452617</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2419452617</sourcerecordid><originalsourceid>FETCH-LOGICAL-c637-ba36ca7c39662cd4d0a7dc40c9b21659c360abe1311415f4000e71a244f321653</originalsourceid><addsrcrecordid>eNotkMtOwzAQRS0EEqWw4QsssUME_Ehtpbu2lIcIKipdsLMceypcpUmxE0H4BX4ah6JZjK7uuaOZQeickmvGubyxBSMJE0k-PUADmvEs4Uy-HaIBIZQlVGbyGJ2EsCGEiFgD9PMHj_H8CyrdOAtYVxYvoyjxom1MvYWAXYVfoglVE_Cna97xqtsBZvjW6QKaCPSZvXAGPzlbQRd1AB1gjCf4uS2jEePgr_AywvXWfYO9ilO9Lkso8WvT2u4UHa11GeDsvw_R6m6-mj0k-eL-cTbJEyO4TArNhdHS8EwIZmxqiZbWpMRkBaNilBkuSNyEckpTOlqn8VSQVLM0XfMe4EN0sR-78_VHC6FRm7r18eCgWEqzdMQElZG63FPG1yF4WKudd1vtO0WJ6n-t-l8rJlQ-5b9FP3AZ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2419452617</pqid></control><display><type>article</type><title>26-LB: Exenatide and Renal Outcomes in Patients with Type 2 Diabetes and Diabetic Kidney Disease: A Multicenter, Randomized, Parallel Study</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>WANG, XIANGYU ; ZHANG, QIAN ; GUAN, MEIPING ; SHENG, SHUYUE ; MO, WEI ; ZOU, MENGCHEN ; LI, JIMIN ; BI, JIANLU ; TANG, XIANYU ; HE, JIALI ; XU, GUGEN ; LI, PING ; ZHANG, HUIJIE ; XUE, YAOMING</creator><creatorcontrib>WANG, XIANGYU ; ZHANG, QIAN ; GUAN, MEIPING ; SHENG, SHUYUE ; MO, WEI ; ZOU, MENGCHEN ; LI, JIMIN ; BI, JIANLU ; TANG, XIANYU ; HE, JIALI ; XU, GUGEN ; LI, PING ; ZHANG, HUIJIE ; XUE, YAOMING</creatorcontrib><description>Aim: This trial aimed to assess the effects of exenatide, a GLP-1RA, on renal outcomes in patients with T2DM and DKD.
Methods: We performed a randomized, parallel study conducted in 4 general hospitals. T2DM patients with an eGFR≥30mL/min/1.73m2 and macroalbuminuria, defined as 24h-urinary albumin-creatinine ratio (UAER) >0.3g/24h, were randomized 1:1 to receive exenatide twice daily plus glargine or lispro insulin plus glargine for 24 weeks. The primary outcome was percentage change in 24h-UAER after 24 weeks of intervention comparing to baseline measurement. The secondary outcomes included the percentage change in urinary ACR, change in 24h-UAER, ACR, HbA1c, FPG, body weight and blood pressure. The safety outcomes include rates of hypoglycemia, adverse events and change in eGFR during the follow up.
Results: Between March 2016 and April 2019, 92 patients were randomized and took at least one dose of study drug. The mean age of the participants was 56 years. At baseline, the median 24h-UAER was 1512.0 mg/24h (IQR 782.5-2818.0), and mean eGFR was 70.4 mL/min/1.73 m2 (SD 23.4). After 24 weeks, exenatide reduced the percentage change of the 24h-UAER (difference between groups was 29.7%, p=0.0255), the percentage change of ACR (difference between groups was 28.4%, p=0.0395) and the absolute change of ACR (difference between groups was 607.8 mg/g, p=0.0209) but had no significant difference on the absolute change of 24h-UAER than the control group. Meanwhile, the body weight declined by 1.3kg with exenatide (difference between groups was 2.7kg, p=0.0001). There was no difference between two groups on the change in HbA1c, FPG, blood pressure or eGFR. Comparing to the control group, lower frequency of hypoglycemia as well as more gastrointestinal adverse events were in intervention group.
Conclusions: Exenatide twice daily plus glargine for 24 weeks resulted in significant reduction of albuminuria in T2DM patients with DKD.</description><identifier>ISSN: 0012-1797</identifier><identifier>EISSN: 1939-327X</identifier><identifier>DOI: 10.2337/db20-26-LB</identifier><language>eng</language><publisher>New York: American Diabetes Association</publisher><subject>Antidiabetics ; Blood pressure ; Body weight ; Creatinine ; Diabetes ; Diabetes mellitus (non-insulin dependent) ; Diabetic nephropathy ; Epidermal growth factor receptors ; Hypoglycemia ; Insulin ; Kidney diseases</subject><ispartof>Diabetes (New York, N.Y.), 2020-06, Vol.69 (Supplement_1)</ispartof><rights>Copyright American Diabetes Association Jun 1, 2020</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids></links><search><creatorcontrib>WANG, XIANGYU</creatorcontrib><creatorcontrib>ZHANG, QIAN</creatorcontrib><creatorcontrib>GUAN, MEIPING</creatorcontrib><creatorcontrib>SHENG, SHUYUE</creatorcontrib><creatorcontrib>MO, WEI</creatorcontrib><creatorcontrib>ZOU, MENGCHEN</creatorcontrib><creatorcontrib>LI, JIMIN</creatorcontrib><creatorcontrib>BI, JIANLU</creatorcontrib><creatorcontrib>TANG, XIANYU</creatorcontrib><creatorcontrib>HE, JIALI</creatorcontrib><creatorcontrib>XU, GUGEN</creatorcontrib><creatorcontrib>LI, PING</creatorcontrib><creatorcontrib>ZHANG, HUIJIE</creatorcontrib><creatorcontrib>XUE, YAOMING</creatorcontrib><title>26-LB: Exenatide and Renal Outcomes in Patients with Type 2 Diabetes and Diabetic Kidney Disease: A Multicenter, Randomized, Parallel Study</title><title>Diabetes (New York, N.Y.)</title><description>Aim: This trial aimed to assess the effects of exenatide, a GLP-1RA, on renal outcomes in patients with T2DM and DKD.
Methods: We performed a randomized, parallel study conducted in 4 general hospitals. T2DM patients with an eGFR≥30mL/min/1.73m2 and macroalbuminuria, defined as 24h-urinary albumin-creatinine ratio (UAER) >0.3g/24h, were randomized 1:1 to receive exenatide twice daily plus glargine or lispro insulin plus glargine for 24 weeks. The primary outcome was percentage change in 24h-UAER after 24 weeks of intervention comparing to baseline measurement. The secondary outcomes included the percentage change in urinary ACR, change in 24h-UAER, ACR, HbA1c, FPG, body weight and blood pressure. The safety outcomes include rates of hypoglycemia, adverse events and change in eGFR during the follow up.
Results: Between March 2016 and April 2019, 92 patients were randomized and took at least one dose of study drug. The mean age of the participants was 56 years. At baseline, the median 24h-UAER was 1512.0 mg/24h (IQR 782.5-2818.0), and mean eGFR was 70.4 mL/min/1.73 m2 (SD 23.4). After 24 weeks, exenatide reduced the percentage change of the 24h-UAER (difference between groups was 29.7%, p=0.0255), the percentage change of ACR (difference between groups was 28.4%, p=0.0395) and the absolute change of ACR (difference between groups was 607.8 mg/g, p=0.0209) but had no significant difference on the absolute change of 24h-UAER than the control group. Meanwhile, the body weight declined by 1.3kg with exenatide (difference between groups was 2.7kg, p=0.0001). There was no difference between two groups on the change in HbA1c, FPG, blood pressure or eGFR. Comparing to the control group, lower frequency of hypoglycemia as well as more gastrointestinal adverse events were in intervention group.
Conclusions: Exenatide twice daily plus glargine for 24 weeks resulted in significant reduction of albuminuria in T2DM patients with DKD.</description><subject>Antidiabetics</subject><subject>Blood pressure</subject><subject>Body weight</subject><subject>Creatinine</subject><subject>Diabetes</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Diabetic nephropathy</subject><subject>Epidermal growth factor receptors</subject><subject>Hypoglycemia</subject><subject>Insulin</subject><subject>Kidney diseases</subject><issn>0012-1797</issn><issn>1939-327X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNotkMtOwzAQRS0EEqWw4QsssUME_Ehtpbu2lIcIKipdsLMceypcpUmxE0H4BX4ah6JZjK7uuaOZQeickmvGubyxBSMJE0k-PUADmvEs4Uy-HaIBIZQlVGbyGJ2EsCGEiFgD9PMHj_H8CyrdOAtYVxYvoyjxom1MvYWAXYVfoglVE_Cna97xqtsBZvjW6QKaCPSZvXAGPzlbQRd1AB1gjCf4uS2jEePgr_AywvXWfYO9ilO9Lkso8WvT2u4UHa11GeDsvw_R6m6-mj0k-eL-cTbJEyO4TArNhdHS8EwIZmxqiZbWpMRkBaNilBkuSNyEckpTOlqn8VSQVLM0XfMe4EN0sR-78_VHC6FRm7r18eCgWEqzdMQElZG63FPG1yF4WKudd1vtO0WJ6n-t-l8rJlQ-5b9FP3AZ</recordid><startdate>20200601</startdate><enddate>20200601</enddate><creator>WANG, XIANGYU</creator><creator>ZHANG, QIAN</creator><creator>GUAN, MEIPING</creator><creator>SHENG, SHUYUE</creator><creator>MO, WEI</creator><creator>ZOU, MENGCHEN</creator><creator>LI, JIMIN</creator><creator>BI, JIANLU</creator><creator>TANG, XIANYU</creator><creator>HE, JIALI</creator><creator>XU, GUGEN</creator><creator>LI, PING</creator><creator>ZHANG, HUIJIE</creator><creator>XUE, YAOMING</creator><general>American Diabetes Association</general><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20200601</creationdate><title>26-LB: Exenatide and Renal Outcomes in Patients with Type 2 Diabetes and Diabetic Kidney Disease: A Multicenter, Randomized, Parallel Study</title><author>WANG, XIANGYU ; ZHANG, QIAN ; GUAN, MEIPING ; SHENG, SHUYUE ; MO, WEI ; ZOU, MENGCHEN ; LI, JIMIN ; BI, JIANLU ; TANG, XIANYU ; HE, JIALI ; XU, GUGEN ; LI, PING ; ZHANG, HUIJIE ; XUE, YAOMING</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c637-ba36ca7c39662cd4d0a7dc40c9b21659c360abe1311415f4000e71a244f321653</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Antidiabetics</topic><topic>Blood pressure</topic><topic>Body weight</topic><topic>Creatinine</topic><topic>Diabetes</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Diabetic nephropathy</topic><topic>Epidermal growth factor receptors</topic><topic>Hypoglycemia</topic><topic>Insulin</topic><topic>Kidney diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>WANG, XIANGYU</creatorcontrib><creatorcontrib>ZHANG, QIAN</creatorcontrib><creatorcontrib>GUAN, MEIPING</creatorcontrib><creatorcontrib>SHENG, SHUYUE</creatorcontrib><creatorcontrib>MO, WEI</creatorcontrib><creatorcontrib>ZOU, MENGCHEN</creatorcontrib><creatorcontrib>LI, JIMIN</creatorcontrib><creatorcontrib>BI, JIANLU</creatorcontrib><creatorcontrib>TANG, XIANYU</creatorcontrib><creatorcontrib>HE, JIALI</creatorcontrib><creatorcontrib>XU, GUGEN</creatorcontrib><creatorcontrib>LI, PING</creatorcontrib><creatorcontrib>ZHANG, HUIJIE</creatorcontrib><creatorcontrib>XUE, YAOMING</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Diabetes (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>WANG, XIANGYU</au><au>ZHANG, QIAN</au><au>GUAN, MEIPING</au><au>SHENG, SHUYUE</au><au>MO, WEI</au><au>ZOU, MENGCHEN</au><au>LI, JIMIN</au><au>BI, JIANLU</au><au>TANG, XIANYU</au><au>HE, JIALI</au><au>XU, GUGEN</au><au>LI, PING</au><au>ZHANG, HUIJIE</au><au>XUE, YAOMING</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>26-LB: Exenatide and Renal Outcomes in Patients with Type 2 Diabetes and Diabetic Kidney Disease: A Multicenter, Randomized, Parallel Study</atitle><jtitle>Diabetes (New York, N.Y.)</jtitle><date>2020-06-01</date><risdate>2020</risdate><volume>69</volume><issue>Supplement_1</issue><issn>0012-1797</issn><eissn>1939-327X</eissn><abstract>Aim: This trial aimed to assess the effects of exenatide, a GLP-1RA, on renal outcomes in patients with T2DM and DKD.
Methods: We performed a randomized, parallel study conducted in 4 general hospitals. T2DM patients with an eGFR≥30mL/min/1.73m2 and macroalbuminuria, defined as 24h-urinary albumin-creatinine ratio (UAER) >0.3g/24h, were randomized 1:1 to receive exenatide twice daily plus glargine or lispro insulin plus glargine for 24 weeks. The primary outcome was percentage change in 24h-UAER after 24 weeks of intervention comparing to baseline measurement. The secondary outcomes included the percentage change in urinary ACR, change in 24h-UAER, ACR, HbA1c, FPG, body weight and blood pressure. The safety outcomes include rates of hypoglycemia, adverse events and change in eGFR during the follow up.
Results: Between March 2016 and April 2019, 92 patients were randomized and took at least one dose of study drug. The mean age of the participants was 56 years. At baseline, the median 24h-UAER was 1512.0 mg/24h (IQR 782.5-2818.0), and mean eGFR was 70.4 mL/min/1.73 m2 (SD 23.4). After 24 weeks, exenatide reduced the percentage change of the 24h-UAER (difference between groups was 29.7%, p=0.0255), the percentage change of ACR (difference between groups was 28.4%, p=0.0395) and the absolute change of ACR (difference between groups was 607.8 mg/g, p=0.0209) but had no significant difference on the absolute change of 24h-UAER than the control group. Meanwhile, the body weight declined by 1.3kg with exenatide (difference between groups was 2.7kg, p=0.0001). There was no difference between two groups on the change in HbA1c, FPG, blood pressure or eGFR. Comparing to the control group, lower frequency of hypoglycemia as well as more gastrointestinal adverse events were in intervention group.
Conclusions: Exenatide twice daily plus glargine for 24 weeks resulted in significant reduction of albuminuria in T2DM patients with DKD.</abstract><cop>New York</cop><pub>American Diabetes Association</pub><doi>10.2337/db20-26-LB</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0012-1797 |
| ispartof | Diabetes (New York, N.Y.), 2020-06, Vol.69 (Supplement_1) |
| issn | 0012-1797 1939-327X |
| language | eng |
| recordid | cdi_proquest_journals_2419452617 |
| source | EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Antidiabetics Blood pressure Body weight Creatinine Diabetes Diabetes mellitus (non-insulin dependent) Diabetic nephropathy Epidermal growth factor receptors Hypoglycemia Insulin Kidney diseases |
| title | 26-LB: Exenatide and Renal Outcomes in Patients with Type 2 Diabetes and Diabetic Kidney Disease: A Multicenter, Randomized, Parallel Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T02%3A09%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=26-LB:%20Exenatide%20and%20Renal%20Outcomes%20in%20Patients%20with%20Type%202%20Diabetes%20and%20Diabetic%20Kidney%20Disease:%20A%20Multicenter,%20Randomized,%20Parallel%20Study&rft.jtitle=Diabetes%20(New%20York,%20N.Y.)&rft.au=WANG,%20XIANGYU&rft.date=2020-06-01&rft.volume=69&rft.issue=Supplement_1&rft.issn=0012-1797&rft.eissn=1939-327X&rft_id=info:doi/10.2337/db20-26-LB&rft_dat=%3Cproquest_cross%3E2419452617%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2419452617&rft_id=info:pmid/&rfr_iscdi=true |